Journey Medical Corporation DERM
6.14
(0.18)
(2.85%)
as of 25 Sep
- Market cap
- $178.4M
- P/E
- 0.0×
Follow DERM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (23.77%) | (36.61%) | (44.03%) | (47.05%) |
+8 more TTM periods Free account |
|
| (6.80%) | (10.86%) | (13.08%) | (11.61%) | ||
ROIC |
(5.89%) | (13.67%) | (15.46%) | (13.15%) | |
Return on Tangible Assets |
(22.60%) | (35.33%) | (38.84%) | (51.96%) | |
Average Days of Receivables |
194.04 | 141.03 | 175.74 | 110.50 | |
Free Cash Flow per Share |
(0.27) | (0.25) | (0.51) | (0.16) | |
Free Cash Flow |
(7.49) | (6.70) | (12.44) | (3.93) | |
Piotroski F-Score |
3.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(9.00%) | (8.03%) | (15.32%) | (5.17%) | |
Accounts Receivable Turnover |
2.63 | 3.01 | 3.09 | 4.15 | |
Accounts Payable Turnover |
2.18 | 1.94 | 1.68 | 1.44 | |
Inventory Turnover |
2.24 | 2.05 | 1.74 | 1.71 | |
Average Days of Payables |
124.72 | 133.94 | 154.40 | 222.88 | |
Days of Inventory on Hand |
126.38 | 151.74 | 167.88 | 213.93 | |
Tax Rate |
0.01 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.73% | 0.68% | 0.78% | 0.92% | |
Selling, General and Administrative Expense of Revenue |
62.94% | 67.88% | 71.73% | 75.03% | |
Share Based Compensation of Revenue |
8.88% | 9.21% | 10.17% | 9.92% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.23 | 0.70 | 1.09 | 0.45 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
2.48 | 2.37 | 2.53 | 2.38 | |
Operating CF per Share |
(0.27) | (0.25) | (0.51) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(8.95%) | (14.82%) | (18.48%) | (14.58%) |
Columns are period end dates